MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy

dc.contributorUniversidade Federal de São Paulo (UNIFESP)
dc.creatorCarvalho, Fabricio de [UNIFESP]
dc.creatorAlves, Veruska L. F. [UNIFESP]
dc.creatorBraga, Walter M. T. [UNIFESP]
dc.creatorXavier, Celso V. [UNIFESP]
dc.creatorColleoni, Gisele W. B. [UNIFESP]
dc.date.accessioned2016-01-24T14:31:00Z
dc.date.accessioned2022-10-07T21:13:14Z
dc.date.available2016-01-24T14:31:00Z
dc.date.available2022-10-07T21:13:14Z
dc.date.created2016-01-24T14:31:00Z
dc.date.issued2013-01-01
dc.identifierCancer Immunology Immunotherapy. New York: Springer, v. 62, n. 1, p. 191-195, 2013.
dc.identifier0340-7004
dc.identifierhttp://repositorio.unifesp.br/handle/11600/35777
dc.identifier10.1007/s00262-012-1376-4
dc.identifierWOS:000313363300018
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/4027732
dc.description.abstractThe exact function of MAGE-C1/CT7 and MAGE-C2/CT10 is not yet understood in multiple myeloma (MM). However, the homologs MAGE-C1/CT7 and MAGE-C2/CT10 genes encode highly immunogeneic cancer/testis antigens (CTAs) and can be potential targets for T cell-based immunotherapy. MAGE-C1/CT7 and MAGE-C2/CT10 mRNA expression were investigated in MM patients, solitary plasmacytomas, monoclonal gammopathies of undetermined significance (MGUS) and bone marrow (BM) aspirates from healthy donors by RT-PCR. MAGE-C1/CT7 and MAGE-C1/CT10 were expressed in 67 and 59 % of the 46 MM analyzed patients. At least one of the genes was expressed in 76 % of MM cases. Solitary plasmacytoma also showed MAGE-C1/CT7 and MAGE-C2/CT10 expression. MAGE-C1/CT7 and MAGE-C2/CT10 were not expressed in normal BM samples, showing restricted expression of these CTA genes in MM, solitary plasmacytoma and MGUS. in the present study, we found high expression of the homologs MAGE-C1/CT7 and MAGE-C2/CT10 in monoclonal gammopathies and speculate whether these genes might represent a valuable therapeutic option for myeloma, in particular for combined immunotherapy.
dc.languageeng
dc.publisherSpringer
dc.relationCancer Immunology Immunotherapy
dc.rightshttp://www.springer.com/open+access/authors+rights?SGWID=0-176704-12-683201-0
dc.rightsAcesso restrito
dc.subjectMAGE-C1/CT7
dc.subjectMAGE-C2/CT10
dc.subjectCancer/testis antigen
dc.subjectConventional RT-PCR
dc.subjectMonoclonal gammopathies
dc.titleMAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy
dc.typeArtigo


Este ítem pertenece a la siguiente institución